Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 1/20 | 0.78 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.78 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.78 |
| ▸ | CTSL | P07711 | 11/20 | 0.73 |
| ▸ | CTSB | P07858 | 7/20 | 0.73 |
| ▸ | CTSK | P43235 | 6/20 | 0.70 |
| ▸ | CTSS | P25774 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8971981 | 1.00 | PSMB1 (0.78) | PSMB1PSMB5PSMB2CTSLCTSB | |
| SCHEMBL1014661 | 1.00 | PSMB1 (0.78) | PSMB1PSMB5PSMB2CTSLCTSB | |
| SCHEMBL7710728 | 1.00 | PSMB1 (0.78) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL7862424 | 0.99 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL14579851 | 0.99 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL5062219 | 0.99 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL14514061 | 0.99 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL13436259 | 0.99 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL2522088 | 0.99 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB | |
| Mg-132 SCHEMBL2535252 | 0.99 | PSMB1 (0.77) | PSMB1PSMB5PSMB2CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3188746-B1 | TARGETING CAPN9 ACTIVITY AS A THERAPEUTIC STRATEGY FOR THE TREATMENT OF MYOFIBROBLAST DIFFERENTIATION AND ASSOCIATED PATHOLOGIES | UNIV JOHNS HOPKINS (US) | 2024-06-19 | — | — | EP | claimed |
| US-20230405124-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF IMMUNE SYSTEM DYSFUNCTION | Oncotracker, Inc. | 2023-12-21 | — | — | US | claimed |
| CN-115551512-A | Use of compounds or compositions comprising NLRP1 inflammatory body activation inhibitors for the treatment of airway inflammation in humans | 南洋理工大学 | 2022-12-30 | — | — | CN | claimed |
| CN-113272294-A | 2, 6-bis (((1H-benzo [ D ] imidazol-2-yl) thio) methyl) pyridine and N2, N6-dibenzylpyridine-2, 6-dicarboxamide derivatives and related compounds as phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer | 雅典学院生物医学研究基金会 | 2021-08-17 | — | — | CN | claimed |
| EP-3662909-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF IMMUNE SYSTEM DYSFUNCTION | Oncotracker, Inc. (US) | 2020-06-10 | — | — | EP | claimed |
| US-20180214553-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF IMMUNE SYSTEM DYSFUNCTION | INSTITUTE FOR MYELOMA & BONE CANCER RESEARCH | 2018-08-02 | — | — | US | claimed |
| EP-3324965-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF IMMUNE SYSTEM DYSFUNCTION | Oncotracker, Inc. (US) | 2018-05-30 | — | — | EP | claimed |
| WO-2017019496-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF IMMUNE SYSTEM DYSFUNCTION | BERENSON JAMES RICHARD (US) | 2017-02-02 | — | — | WO | claimed |
| US-8377886-B2 | Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2013-02-19 | — | — | US | claimed |
| US-20260091118-A1 | Methods for Preparation and Use of BacPROTACs for Targeted Protein Degradation in Mycobacteria and Other Bacteria | WASHINGTON UNIVERSITY (US) | 2026-04-02 | — | — | US | disclosed |
| CN-114487405-B | Application of E3 ubiquitin ligase RBCK1 in preparing medicament for treating liver cancer | 南昌大学第二附属医院 | 2025-02-11 | — | — | CN | disclosed |
| WO-2025028606-A1 | CULTURE MEDIUM FOR HUMAN CELLS, AND METHOD FOR CULTURING HUMAN HEMATOPOIETIC STEM CELLS | 国立大学法人筑波大学 | 2025-02-06 | — | — | WO | disclosed |
| CN-113825832-B | Amplification method for in-vitro induction of CD4+Foxp3+CD69+ Treg and application thereof | 浙江大学 | 2024-12-13 | — | — | CN | disclosed |
| CN-118909952-A | Protein degradation inhibitors for improved production | 隆扎有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20040253245-A1 | Modulators | CELLDEX THERAPEUTICS LIMITED (GB) | 2004-12-16 | — | — | US | disclosed |
| EP-1465924-A2 | MODULATORS OF NOTCH IC PROTEASE ACTIVITY FOR USE IN IMMUNOTHERAPY | Lorantis Limited (GB) | 2004-10-13 | — | — | EP | disclosed |
| EP-1446424-A2 | COMPOSITION COMPRISING INHIBITORS OF THE NOTCH SIGNALLING PATHWAY FOR THE MODULATION OF THE IMMUNE SYSTEM | Lorantis Limited (GB) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003041735-A2 | COMPOSOTION COMPRISING INHIBITORS OF THE NOTCH SIGNALLING PATHWAY FOR THE MODULATION OF THE IMMUNE SYSTEM | LORANTIS LIMITED (GB) | 2003-05-22 | — | — | WO | disclosed |
| WO-2003029293-A2 | MODULATORS OF NOTCH IC PROTEASE ACTIVITY FOR USE IN IMMUNOTHERAPY | LORANTIS LIMITED (GB) | 2003-04-10 | — | — | WO | disclosed |
| EP-1153612-A1 | ANTICANCER AGENT POTENTIATORS | Tsuruo, Takashi (US) | 2001-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091118-A1 | Methods for Preparation and Use of BacPROTACs for Targeted Protein Degradation in Mycobacteria and Other Bacteria | CLPP, DNPEP, NPEPPS | PSMB1 29/4885PSMB5 28/4885PSMB2 6/4885 |
| US-20040253245-A1 | Modulators | NOTCH1, BID, GSAP | PSMB1 484/4885PSMB5 680/4885PSMB2 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.